Navigation Links
AIBS to cohost symposium on evolution, disease and human health
Date:9/18/2007

The American Institute of Biological Sciences (AIBS), in conjunction with the National Evolutionary Synthesis Center, will host the fourth annual symposium on evolution on December 1, 2007, at the Hyatt Regency Hotel in Atlanta, Georgia. The symposium, titled Evolution: Applications in Human Health and Populations, is part of the 2007 Professional Development Conference sponsored by the National Association of Biology Teachers.

The aim of the symposium is to familiarize biology teachers with current research on evolutions role in disease, medicine, and human health, and to explore the ethical questions attendant to that role.

The following eminent scientists will make presentations:

  • Gregory Wray, director of the Institute for Genome Sciences and Policy at Duke University, will give a presentation titled Genomic Perspectives on the Evolution of Human Health and Disease. Wray has a long-standing interest in the evolution of developmental mechanisms. Through his research, he has addressed the evolution of life history modes and larvae in echinoderms, the evolution of embryonic patterning mechanisms in metazoans, the timing of the metazoan radiation, and the role of regulatory gene expression in testing hypotheses of anatomical homology. His current projects focus on the evolution of developmental gene networks and mechanisms of transcriptional regulation. These projects use a variety of approaches and organisms to ask questions about the role that developmental processes play in the evolution of the genotype-phenotype relationship.
  • Carlos Bustamante, assistant professor of Biological Statistics and Computational Biology at Cornell University, will give a presentation titled Sign, Sign, Everywhere a Sign: Interpreting Evident for Recent Natural Selection on the Human Genome. Bustamantes work focuses on developing statistical methods for inference in population and comparative genomics. He is particularl
    '/>"/>

Contact: Samantha J. Katz
skatz@aibs.org
202-628-1500
American Institute of Biological Sciences
Source:Eurekalert

Page: 1 2 3 4

Related biology news :

1. Institute for Systems Biology Symposium Addresses Need for Better Computational Tools
2. Amazon symposium to address large-scale conservation
3. Perception gene tracked humanitys evolution, scientists say
4. Neuronal traffic jam marks early Alzheimers disease
5. Scientists detect probable genetic cause of some Parkinsons disease cases
6. Transplantation Of Monkey Embryonic Stem Cells Reverses Parkinson Disease In Primates
7. Ecological destruction fuels emerging diseases
8. Newly discovered virus linked to childhood lung disorders and Kawasaki disease
9. Finding Cures For Tropical Diseases: Is Open Source An Answer?
10. U of M researcher examines newly emerging deadly disease
11. Marburg virus disease in Angola - update
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology News(10 mins):The pitch of blue whale songs is declining around the world, scientists discover 2The pitch of blue whale songs is declining around the world, scientists discover 3MSU research may lead to new ways to control honeybee parasite 2KV Pharmaceutical Company Purdue Pharma L P Settle OxyContin 28R 29 Dispute 48392 1KV Pharmaceutical Company Purdue Pharma L P Settle OxyContin 28R 29 Dispute 48392 2KV Pharmaceutical Company Purdue Pharma L P Settle OxyContin 28R 29 Dispute 48392 3KV Pharmaceutical Company Purdue Pharma L P Settle OxyContin 28R 29 Dispute 48392 4KV Pharmaceutical Company Purdue Pharma L P Settle OxyContin 28R 29 Dispute 48392 5KV Pharmaceutical Company Purdue Pharma L P Settle OxyContin 28R 29 Dispute 48392 6Two Year Data Show Patients Receiving SIMPONI 28TM 29 28golimumab 29 Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis a 4578 1Two Year Data Show Patients Receiving SIMPONI 28TM 29 28golimumab 29 Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis a 4578 2Two Year Data Show Patients Receiving SIMPONI 28TM 29 28golimumab 29 Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis a 4578 3Two Year Data Show Patients Receiving SIMPONI 28TM 29 28golimumab 29 Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis a 4578 4Two Year Data Show Patients Receiving SIMPONI 28TM 29 28golimumab 29 Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis a 4578 5Two Year Data Show Patients Receiving SIMPONI 28TM 29 28golimumab 29 Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis a 4578 6Two Year Data Show Patients Receiving SIMPONI 28TM 29 28golimumab 29 Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis a 4578 7Two Year Data Show Patients Receiving SIMPONI 28TM 29 28golimumab 29 Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis a 4578 8Two Year Data Show Patients Receiving SIMPONI 28TM 29 28golimumab 29 Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis a 4578 9Two Year Data Show Patients Receiving SIMPONI 28TM 29 28golimumab 29 Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis a 4578 10Two Year Data Show Patients Receiving SIMPONI 28TM 29 28golimumab 29 Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis a 4578 11Two Year Data Show Patients Receiving SIMPONI 28TM 29 28golimumab 29 Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis a 4578 12Landmark Study Published in New England Journal of Medicine 48389 1Landmark Study Published in New England Journal of Medicine 48389 2Landmark Study Published in New England Journal of Medicine 48389 3